Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 2/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23528156 | 0.99 | PDGFRA (0.72) | PDGFRAPDGFRBFGFR2KDREGFR | |
| SCHEMBL901281 | 0.93 | PDGFRA (0.68) | PDGFRAPDGFRBFGFR2KDREGFR | |
| SCHEMBL14540576 | 0.92 | PDGFRA (0.62) | PDGFRAPDGFRBFGFR2KDREGFR | |
| SCHEMBL13980801 | 0.90 | PDGFRA (0.60) | PDGFRAPDGFRBFGFR2KDREGFR | |
| SCHEMBL14139303 | 0.90 | PDGFRA (0.61) | PDGFRAPDGFRBFGFR2KDR | |
| Fluorobenzene SCHEMBL28724473 | 0.90 | FGFR2 (0.65) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL14139343 | 0.90 | PDGFRA (0.61) | PDGFRAPDGFRBFGFR2KDR | |
| SCHEMBL7486400 | 0.89 | FGFR2 (0.84) | PDGFRAPDGFRBFGFR2KDREGFR | |
| SCHEMBL2747998 | 0.89 | PDGFRB (0.71) | PDGFRAPDGFRBFGFR2KDREGFR | |
| SCHEMBL4141203 | 0.89 | FGFR2 (0.60) | PDGFRAPDGFRBFGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 724 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658271-A1 | IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE | Handa Oncology, LLC (US) | 2025-12-10 | — | — | EP | claimed |
| CN-115784987-B | Compound related to pneumonia as well as preparation method and application thereof and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2025-05-27 | — | — | CN | claimed |
| WO-2024163400-A1 | IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2024-08-08 | — | — | WO | claimed |
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2024-06-13 | — | — | US | claimed |
| EP-4313048-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | Biocon Limited (IN) | 2024-02-07 | — | — | EP | claimed |
| WO-2023222946-A1 | PROCESS FOR THE PREPARATION OF CABOZANTINIB | FERMION OY (FI) | 2023-11-23 | — | — | WO | claimed |
| CN-116891455-A | N-substituted phenyl-pyridazinone-3-formamide compound, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-10-17 | — | — | CN | claimed |
| CN-115784987-A | Compound related to pneumonia, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-03-14 | — | — | CN | claimed |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | NATCO PHARMA LIMITED (IN) | 2022-11-15 | — | — | US | claimed |
| WO-2022201079-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2022-09-29 | — | — | WO | claimed |
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2021-06-24 | — | — | US | claimed |
| CN-111217745-B | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2021-05-11 | — | — | CN | claimed |
| CN-111217745-A | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2020-06-02 | — | — | CN | claimed |
| CN-110903240-A | Preparation method of broad-spectrum anticancer drug cabozantinib | 上海玉函化工有限公司 | 2020-03-24 | — | — | CN | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | claimed |
| US-20260138953-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4294804-B1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260049059-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | SYNTHON BV (NL) | 2026-02-19 | — | — | US | disclosed |
| US-12552749-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12522567-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-01-13 | — | — | US | disclosed |
| US-12516025-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-12516026-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4658271-A1 | IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE | Handa Oncology, LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367186-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250340515-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4622961-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | Synthon B.V. (NL) | 2025-10-01 | — | — | EP | disclosed |
| US-12415784-B2 | Cabozantinib compositions and methods of use | HANDA ONCOLOGY, LLC (US) | 2025-09-16 | — | — | US | disclosed |
| US-12404244-B2 | Pan-KIT kinase inhibitor having quinoline structure and application thereof | Tarapeutics Science Inc. (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20250262200-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250257036-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250250238-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250243166-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025125873-A1 | PROCEDURE FOR THE PURIFICATION OF CABOZANTINIB | STERLING CHEMICAL MALTA LTD. (MT) | 2025-06-19 | — | — | WO | disclosed |
| US-20250186452-A1 | NOVEL USE OF QUINOLINE COMPOUND | Tarapeutics Science Inc. (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-115784987-B | Compound related to pneumonia as well as preparation method and application thereof and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2025-05-27 | — | — | CN | disclosed |
| US-20250134880-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | EXELIXIS INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12275706-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119775204-A | Continuous synthesis method of cabozitinib in microreactor | 皖西学院 | 2025-04-08 | — | — | CN | disclosed |
| EP-3570840-B1 | COMBINATIONS OF CABOZANTINIB AND ATEZOLIZUMAB FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | EXELIXIS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250084037-A1 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | PHARMORPHIX (GB) | 2025-03-13 | — | — | US | disclosed |
| US-20250066305-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12227511-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-02-18 | — | — | US | disclosed |
| US-20250017916-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS INC (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4491181-A1 | NOVEL USE OF QUINOLINE COMPOUND | Tarapeutics Science Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| CN-112390749-B | Synthetic method of cabozitinib and intermediate thereof | 鲁南制药集团股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-12128039-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240316030-A1 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | EXELIXIS INC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240307367-A1 | Liquid Dosage Forms to Treat Cancer | EXELIXIS INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240287002-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS INC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2024-08-22 | — | — | US | disclosed |
| WO-2024163400-A1 | IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-112979544-B | Preparation method of cabozitinib or salt thereof | 江苏先声药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-12016854-B2 | Liquid dosage forms to treat cancer | EXELIXIS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240189298-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2024-06-13 | — | — | US | disclosed |
| WO-2024110606-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | SYNTHON B.V. (NL) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024110606-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | SYNTHON B.V. (NL) | 2024-05-30 | — | — | WO | disclosed |
| US-20240156803-A1 | Method of Treating Cancer | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-16 | — | — | US | disclosed |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240156804-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11969419-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117771363-A | Carbotinib and alemtuzumab combination for treating cancer | 埃克塞里艾克西斯公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4313048-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | Biocon Limited (IN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117440951-A | Pyridone compounds and methods of use | 埃克塞里艾克西斯公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-3896059-B1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | TARAPEUTICS SCIENCE INC (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-117343046-A | Novel 3-oxo-4-substituted aryl-3, 4-dihydropyrazine-2-carboxamide compound and application thereof | 辽宁大学 | 2024-01-05 | — | — | CN | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117205312-A | Carbotinib and alemtuzumab combination for treating cancer | 埃克塞里艾克西斯公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117205313-A | Carbotinib and alemtuzumab combination for treating cancer | 埃克塞里艾克西斯公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230391789-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-07 | — | — | US | disclosed |
| WO-2023222946-A1 | PROCESS FOR THE PREPARATION OF CABOZANTINIB | FERMION OY (FI) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222946-A1 | PROCESS FOR THE PREPARATION OF CABOZANTINIB | FERMION OY (FI) | 2023-11-23 | — | — | WO | disclosed |
| CN-116891455-A | N-substituted phenyl-pyridazinone-3-formamide compound, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-10-17 | — | — | CN | disclosed |
| US-20230314440-A1 | METHOD OF TREATING CANCER | EXELIXIS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230314440-A1 | METHOD OF TREATING CANCER | EXELIXIS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230314440-A1 | METHOD OF TREATING CANCER | EXELIXIS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230301980-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230301978-A1 | Liquid Dosage Forms to Treat Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230301978-A1 | Liquid Dosage Forms to Treat Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230301978-A1 | Liquid Dosage Forms to Treat Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230301980-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230301980-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| CN-116763787-A | New application of quinoline compound | 安徽中科拓苒药物科学研究有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-11702425-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-07-18 | — | — | US | disclosed |
| US-11702425-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-07-18 | — | — | US | disclosed |
| US-11702425-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-07-18 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181559-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230181559-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230181559-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230167063-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167063-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167063-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230149384-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149384-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149384-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-111303024-B | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11612597-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| CN-115784987-A | Compound related to pneumonia, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-03-14 | — | — | CN | disclosed |
| US-11564915-B2 | Cabozantinib dosage form and use in the treatment of cancer | EXELIXIS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11564915-B2 | Cabozantinib dosage form and use in the treatment of cancer | EXELIXIS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-115605478-A | Compounds and methods of use | 埃克塞里艾克西斯公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4110779-A1 | COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220370436-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS INC (US) | 2022-11-24 | — | — | US | disclosed |
| US-11504363-B2 | Method of treating cancer and bone cancer pain | EXELIXIS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11504362-B2 | Liquid dosage forms to treat cancer | EXELIXIS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | NATCO PHARMA LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| EP-2621481-B2 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022201079-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2022-09-29 | — | — | WO | disclosed |
| US-11433064-B2 | Methods of using c-Met modulators | EXELIXIS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433064-B2 | Methods of using c-Met modulators | EXELIXIS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022178205-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-3174854-B1 | METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS | EXELIXIS INC (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220259151-A9 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | PHARMORPHIX (GB) | 2022-08-18 | — | — | US | disclosed |
| US-20220259151-A9 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | PHARMORPHIX (GB) | 2022-08-18 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114787144-A | Pyridone compounds and methods for modulating protein kinases | 埃克塞里艾克西斯公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-109988110-B | 4-phenoxy quinoline sulfonylurea compound, intermediate for synthesizing the compound and its preparation method and use | 威海海洋生物医药产业技术研究院有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-4019498-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Exelixis, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-2981263-B1 | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-2981263-B1 | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220194902-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | EXELIXIS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20220194902-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | EXELIXIS, INC. | 2022-06-23 | — | — | US | disclosed |
| EP-4014971-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | Exelixis, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4014971-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | Exelixis, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-111440177-B | Substituted pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2022-06-14 | — | — | CN | disclosed |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114456109-A | Preparation method and application of high-purity cabozantinib malate | 北京四环制药有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109988108-B | Preparation method of cabozantinib | 江苏豪森药业集团有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-2387563-B2 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11298349-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11298349-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220087999-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS INC (US) | 2022-03-24 | — | — | US | disclosed |
| CN-114209699-A | C-MET modulator pharmaceutical compositions | 埃克塞里艾克西斯公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114129566-A | Inhibitors of MET, VEGFR and RET for the treatment of lung adenocarcinoma | 埃克塞里艾克西斯公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| US-11261160-B2 | Process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2022-03-01 | — | — | US | disclosed |
| US-20220056138-A1 | Combinations of Cabozantinib and Atezolizumab to Treat Cancer | EXELIXIS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220056138-A1 | Combinations of Cabozantinib and Atezolizumab to Treat Cancer | EXELIXIS, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022040555-A2 | METHOD OF TREATING CANCER | EXELIXIS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220031688-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220031688-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220033357-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220033357-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220023284-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220023284-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210403431-A1 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-12-30 | — | — | US | disclosed |
| US-20210403431-A1 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-12-30 | — | — | US | disclosed |
| US-11198731-B2 | Combinations of cabozantinib and atezolizumab to treat cancer | EXELIXIS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210379050-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210379050-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2021-12-09 | — | — | US | disclosed |
| EP-3914356-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3906921-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | Exelixis, Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-2673262-B1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-2673262-B1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210332013-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS INC (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210332013-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS INC (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3896059-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-2593090-B1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | EXELIXIS INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210309668-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-10-07 | — | — | US | disclosed |
| US-20210309668-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-10-07 | — | — | US | disclosed |
| US-11124481-B2 | Method of preparing fluorine-18 labeled Cabozantinib and its analogs | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124481-B2 | Method of preparing fluorine-18 labeled Cabozantinib and its analogs | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123338-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123338-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11116759-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11116759-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-11091440-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091439-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091439-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091440-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-106715397-B | Method for preparing fluorine-18 labeled cabozantinib and analogs thereof | 埃克塞里艾克西斯公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11065240-B2 | Drug combinations to treat multiple myeloma | EXELIXIS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065240-B2 | Drug combinations to treat multiple myeloma | EXELIXIS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2021-06-24 | — | — | US | disclosed |
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2021-06-24 | — | — | US | disclosed |
| US-20210163416-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210163416-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210161885-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210161885-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210154185-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210154185-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210139430-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210139430-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-111217745-B | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2021-05-11 | — | — | CN | disclosed |
| CN-111217745-B | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2021-05-11 | — | — | CN | disclosed |
| WO-2021062245-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | EXELIXIS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-3134084-B1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS INC (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3134084-B1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20210024467-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2021-01-28 | — | — | US | disclosed |
| US-20210024467-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2021-01-28 | — | — | US | disclosed |
| WO-2021012717-A1 | ANTITUMOR COMPOUND USED AS AXL INHIBITOR AND USE THEREOF | 南京华威医药科技集团有限公司 | 2021-01-28 | — | — | WO | disclosed |
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200392110-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-3415501-B9 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-20200330451-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200330451-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200330450-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200330450-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200268737-A1 | Liquid Dosage Forms to Treat Cancer | EXELIXIS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200268737-A1 | Liquid Dosage Forms to Treat Cancer | EXELIXIS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20200255382-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255382-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10736886-B2 | Methods of using c-Met modulators | EXELIXIS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736886-B2 | Methods of using c-Met modulators | EXELIXIS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2020154610-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154610-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-3676254-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | AbbVie Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2020118753-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020118753-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-18 | — | — | WO | disclosed |
| US-20200190032-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2020-06-18 | — | — | US | disclosed |
| US-20200190032-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2020-06-18 | — | — | US | disclosed |
| CN-111217745-A | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2020-06-02 | — | — | CN | disclosed |
| CN-111217745-A | Preparation method of cabozantinib | 漯河医学高等专科学校 | 2020-06-02 | — | — | CN | disclosed |
| US-20200163954-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163954-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200121671-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200121671-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3634413-A1 | LIQUID DOSAGE FORMS TO TREAT CANCER | Exelixis, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200108059-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200108059-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS INC (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3415501-B1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-110903240-A | Preparation method of broad-spectrum anticancer drug cabozantinib | 上海玉函化工有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110818633-A | Malate and crystal form thereof | 埃克塞里艾克西斯公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2020027723-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020027723-A1 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-06 | — | — | WO | disclosed |
| US-10548888-B2 | C-Met modulator pharmaceutical compositions | EXELIXIS (US) | 2020-02-04 | — | — | US | disclosed |
| US-10548888-B2 | C-Met modulator pharmaceutical compositions | EXELIXIS (US) | 2020-02-04 | — | — | US | disclosed |
| US-10543206-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10543206-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| CN-110678180-A | Liquid dosage form for treating cancer | 埃克塞里艾克西斯公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10501442-B2 | Quinoline derivative | ONO PHARMACEUTICALS CO., LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| US-20190352403-A1 | Combinations of Cabozantinib and Atezolizumab to Treat Cancer | EXELIXIS, INC. | 2019-11-21 | — | — | US | disclosed |
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3551612-A1 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF | MSN Laboratories Private Limited, R&D Center (IN) | 2019-10-16 | — | — | EP | disclosed |
| EP-2621481-B1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-2621481-B1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20190218182-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218182-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190151302-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10273211-B2 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273211-B2 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190091215-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190091215-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2019-03-14 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-10208022-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-2892532-B1 | INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA | EXELIXIS INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20190030021-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20190030021-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-10166225-B2 | Method for treating osteoporosis | EXELIXIS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-10166225-B2 | Method for treating osteoporosis | EXELIXIS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-10159666-B2 | Dosing of cabozantinib formulations | EXELIXIS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2018227119-A1 | LIQUID DOSAGE FORMS TO TREAT CANCER | EXELIXIS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| US-10123999-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180311229-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-20180237378-A1 | Asymmetric Bisamidation of Malonic Ester Derivatives | SANDOZ AG (CH) | 2018-08-23 | — | — | US | disclosed |
| US-10039757-B2 | C-Met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039757-B2 | C-Met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039757-B2 | C-Met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10034873-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034873-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034873-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018136796-A1 | COMBINATIONS OF CABOZANTINIB AND ATEZOLIZUMAB TO TREAT CANCER | EXELIXIS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136796-A1 | COMBINATIONS OF CABOZANTINIB AND ATEZOLIZUMAB TO TREAT CANCER | EXELIXIS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3337786-A1 | ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES | Sandoz AG (CH) | 2018-06-27 | — | — | EP | disclosed |
| WO-2018104954-A1 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-06-14 | — | — | WO | disclosed |
| US-9994549-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-12 | — | — | US | disclosed |
| WO-2018100190-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING RENAL CELL CARCINOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-06-07 | — | — | WO | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180037552-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-02-08 | — | — | US | disclosed |
| US-20180037552-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-02-08 | — | — | US | disclosed |
| US-20180037552-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-02-08 | — | — | US | disclosed |
| EP-3275443-A1 | METHOD FOR TREATING OSTEOPOROSIS | Exelixis, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275443-A1 | METHOD FOR TREATING OSTEOPOROSIS | Exelixis, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9861624-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9861624-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20180002289-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20180002289-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9809549-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809549-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809549-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170275251-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275251-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275251-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170266178-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266178-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266178-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2017-09-21 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170224672-A1 | Drug Combinations to Treat Multiple Myeloma | EXELIXIS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224672-A1 | Drug Combinations to Treat Multiple Myeloma | EXELIXIS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224672-A1 | Drug Combinations to Treat Multiple Myeloma | EXELIXIS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9724342-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724342-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724342-B2 | C-met modulator pharmaceutical compositions | EXELIXIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
| US-20170217896-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
| US-9717720-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717720-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9717720-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-3177311-A1 | DRUG COMBINATIONS TO TREAT MULTIPLE MYELOMA | Exelixis, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3174854-A1 | METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS | Exelixis, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3174854-A1 | METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS | Exelixis, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2758057-B1 | METHOD FOR TREATING OSTEOPOROSIS | EXELIXIS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2758057-B1 | METHOD FOR TREATING OSTEOPOROSIS | EXELIXIS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20170143689-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143689-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143689-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2017-05-25 | — | — | US | disclosed |
| CN-106715397-A | Method of preparing fluorine-18 labeled cabozantinib and its analogs | 埃克塞里艾克西斯公司 | 2017-05-24 | — | — | CN | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-20170057921-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057921-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057921-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-3134084-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | Exelixis, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2017029362-A1 | ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES | SANDOZ AG (CH) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029362-A1 | ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES | SANDOZ AG (CH) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9573935-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20170042880-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042880-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042880-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2017-02-16 | — | — | US | disclosed |
| EP-3119476-A1 | DOSING OF CABOZANTINIB FORMULATIONS | Exelixis, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160220554-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160220554-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160220554-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-3045453-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3045453-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-3026045-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-20160082019-A1 | Drug Combinations to Treat Cancer | EXELIXIS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160082019-A1 | Drug Combinations to Treat Cancer | EXELIXIS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160082019-A1 | Drug Combinations to Treat Cancer | EXELIXIS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160051532-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2983639-A1 | DRUG COMBINATIONS TO TREAT CANCER | Exelixis, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2016022697-A1 | DRUG COMBINATIONS TO TREAT MULTIPLE MYELOMA | EXELIXIS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022697-A1 | DRUG COMBINATIONS TO TREAT MULTIPLE MYELOMA | EXELIXIS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| EP-2981263-A1 | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2016-02-10 | — | — | EP | disclosed |
| WO-2016019285-A1 | METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS | EXELIXIS, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016019285-A1 | METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS | EXELIXIS, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016019285-A1 | METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS | EXELIXIS, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160022662-A1 | Cabozantinib Dosage Form and Use in the Treatment of Cancer | EXELIXIS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022662-A1 | Cabozantinib Dosage Form and Use in the Treatment of Cancer | EXELIXIS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022662-A1 | Cabozantinib Dosage Form and Use in the Treatment of Cancer | EXELIXIS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2970126-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE | Exelixis, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160000772-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000772-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000772-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015164869-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015164869-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015142928-A1 | DOSING OF CABOZANTINIB FORMULATIONS | EXELIXIS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015142928-A1 | DOSING OF CABOZANTINIB FORMULATIONS | EXELIXIS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126935-B2 | Aurora kinase modulators and methods of use | AMGEN INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150238477-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150238477-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150238477-A1 | Method of Treating Lung Adenocarcinoma | EXELIXIS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150202196-A1 | Methods of Using C-Met Modulators | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-07-23 | — | — | US | disclosed |
| US-20150202196-A1 | Methods of Using C-Met Modulators | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-07-23 | — | — | US | disclosed |
| US-20150202196-A1 | Methods of Using C-Met Modulators | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-07-23 | — | — | US | disclosed |
| US-20150196545-A1 | Method of Treating Cancer | EXELIXIS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196545-A1 | Method of Treating Cancer | EXELIXIS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196545-A1 | Method of Treating Cancer | EXELIXIS INC (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2892532-A1 | INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA | Exelixis, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20150133494-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133494-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133494-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2844254-A1 | A DUAL MET - VEGF MODULATOR FOR TREATING OSTEOLYTIC BONE METASTASES | Exelixis, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150057310-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057310-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057310-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140330170-A1 | Method of Quantifying Cancer Treatment | EXELIXIS INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330170-A1 | Method of Quantifying Cancer Treatment | EXELIXIS INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330170-A1 | Method of Quantifying Cancer Treatment | EXELIXIS INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8877776-B2 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877776-B2 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877776-B2 | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140323522-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323522-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323522-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2014-10-30 | — | — | US | disclosed |
| WO-2014165786-A1 | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165779-A1 | DRUG COMBINATIONS TO TREAT CANCER | EXELIXIS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165779-A1 | DRUG COMBINATIONS TO TREAT CANCER | EXELIXIS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165786-A1 | CABOZANTINIB DOSAGE FORM AND USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014145693-A1 | METABOLITES OF N-[3-FLUORO-4-({ 6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145693-A1 | METABOLITES OF N-[3-FLUORO-4-({ 6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]QUINOLIN-4-YL}OXY)PHENYL]-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145715-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2776033-A1 | DUAL INHIBITOR OF MET AND VEGF FOR TREATING CANCER | Exelixis, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2775921-A1 | METHOD OF QUANTIFYING CANCER TREATMENT | Exelixis, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| EP-2768796-A1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | Exelixis, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140228401-A1 | Method for Treating Osteoporosis | EXELIXIS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228401-A1 | Method for Treating Osteoporosis | EXELIXIS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228401-A1 | Method for Treating Osteoporosis | EXELIXIS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2758057-A1 | METHOD FOR TREATING OSTEOPOROSIS | Exelixis, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140179736-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179736-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179736-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140121239-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2392565-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2014039971-A1 | INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039971-A1 | INHIBITORS OF MET, VEGFR AND RET FOR USE IN THE TREATMENT OF LUNG ADENOCARCINOMA | EXELIXIS, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20140057943-A1 | Method of Treating Cancer | EXELIXIX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057943-A1 | Method of Treating Cancer | EXELIXIX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057943-A1 | Method of Treating Cancer | EXELIXIX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057908-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057908-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057908-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130337015-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2013-12-19 | — | — | US | disclosed |
| EP-2673262-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Exelixis, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013180949-A1 | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE | XI NING (US) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013166296-A1 | A DUAL MET - VEGF MODULATOR FOR TREATING OSTEOLYTIC BONE METASTASES | EXELIXIS, INC. (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013166296-A1 | A DUAL MET - VEGF MODULATOR FOR TREATING OSTEOLYTIC BONE METASTASES | EXELIXIS, INC. (US) | 2013-11-07 | — | — | WO | disclosed |
| EP-2392564-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2392564-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2621481-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION- RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621483-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2612853-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2609919-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-2594566-A1 | NITROGENATED AROMATIC HETEROCYCLIC RING DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| EP-2593090-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | Exelixis, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| WO-2013070890-A1 | DUAL INHIBITOR OF MET AND VEGF FOR TREATING CANCER | EXELIXIS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070890-A1 | DUAL INHIBITOR OF MET AND VEGF FOR TREATING CANCER | EXELIXIS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070903-A1 | METHOD OF QUANTIFYING CANCER TREATMENT | EXELIXIS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013059788-A1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059788-A1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2258366-B1 | Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | KIRIN PHARMA KK (JP) | 2013-04-03 | — | — | EP | disclosed |
| WO-2013043840-A1 | METHOD FOR TREATING OSTEOPOROSIS | EXELIXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013032797-A2 | OXETANE 3,3-DICARBOXAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | NEW HOPE R & D BIOSCIENCE, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2387563-B1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8324245-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324245-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324245-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20120282179-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282179-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282179-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120252840-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252840-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252840-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2012109510-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2461810-A1 | METHODS OF USING C-MET MODULATORS | Exelixis, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2012044572-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION- RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120070368-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070368-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070368-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2012009722-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2392565-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392565-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392564-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392564-A1 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110294837-A1 | Aurora Kinase Modulators and Methods of Use | AMGEN INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110294837-A1 | Aurora Kinase Modulators and Methods of Use | AMGEN INC. | 2011-12-01 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2387563-A1 | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Exelixis, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1673085-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1673085-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110252754-A1 | HORSEBACK RIDING SPUR MECHANISM | COOK KARL | 2011-10-20 | — | — | US | disclosed |
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-2023926-B1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer Pharma AG (DE) | 2011-10-12 | — | — | EP | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105747-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2258366-A2 | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | Kirin Pharma Kabushiki Kaisha (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258366-A2 | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | Kirin Pharma Kabushiki Kaisha (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2213661-A1 | c-Met Modulators and Methods of Use | Exelixis Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213661-A1 | c-Met Modulators and Methods of Use | Exelixis Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2210607-A1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | Exelixis Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010083414-A1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUIN0LIN-4-YL] OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEROF FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083414-A1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUIN0LIN-4-YL] OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEROF FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010019473-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019473-A1 | AURORA KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
| US-7612092-B2 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| EP-1411046-B1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN PHARMA KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-1411046-B1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN PHARMA KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-2088141-A2 | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | Kirin Pharma Kabushiki Kaisha (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-2088141-A2 | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same | Kirin Pharma Kabushiki Kaisha (JP) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009096435-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| EP-1874759-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| EP-2023926-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer HealthCare AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-20080312221-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312221-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312221-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7425564-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425564-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425564-B2 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1652847-B1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN PHARMA KK (JP) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| EP-1874759-A1 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7211587-B2 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6821987-B2 | 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1411046-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167063-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | PDGFRA 3033/4885PDGFRB 4238/4885FGFR2 957/4885 |
| US-10123999-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | HAX1, HRH1, HRH2 | PDGFRA 3972/4885PDGFRB 3455/4885FGFR2 4494/4885 |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRA 63/4885PDGFRB 30/4885FGFR2 590/4885 |
| US-11969419-B2 | Method of treating cancer | MET, HGF, ACP3 | PDGFRA 109/4885PDGFRB 70/4885FGFR2 59/4885 |
| US-20240156803-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885PDGFRB 70/4885FGFR2 59/4885 |
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | PDGFRA 2690/4885PDGFRB 4141/4885FGFR2 1975/4885 |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | PDGFRA 844/4885PDGFRB 750/4885FGFR2 1996/4885 |
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRA 3965/4885PDGFRB 3177/4885FGFR2 4410/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885PDGFRB 30/4885FGFR2 590/4885 |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | GNG2, GCG, FRG1 | PDGFRA 3131/4885PDGFRB 3824/4885FGFR2 969/4885 |
| US-11123338-B2 | C-met modulator pharmaceutical compositions | MET, HGFAC, HGF | PDGFRA 143/4885PDGFRB 39/4885FGFR2 668/4885 |
| US-20190091215-A1 | Method of Treating Cancer | MET, FLT1, TIE1 | PDGFRA 209/4885PDGFRB 191/4885FGFR2 74/4885 |
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRA 182/4885PDGFRB 90/4885FGFR2 529/4885 |
| US-20150238477-A1 | Method of Treating Lung Adenocarcinoma | RET, MET, KIF5B | PDGFRA 266/4885PDGFRB 284/4885FGFR2 23/4885 |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRA 1862/4885PDGFRB 2840/4885FGFR2 3966/4885 |
| US-20240316030-A1 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | TPO, OGFR, CALCR | PDGFRA 2352/4885PDGFRB 2385/4885FGFR2 1963/4885 |
| US-20200330451-A1 | Methods of Using C-Met Modulators | MET, KRAS, HGF | PDGFRA 174/4885PDGFRB 84/4885FGFR2 203/4885 |
| US-11564915-B2 | Cabozantinib dosage form and use in the treatment of cancer | ABL1, FER, FLT3 | PDGFRA 59/4885PDGFRB 62/4885FGFR2 118/4885 |
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | PDK1, PDHB, MPC2 | PDGFRA 641/4885PDGFRB 494/4885FGFR2 289/4885 |
| US-20160051532-A1 | Method of Treating Cancer | MET, FLT1, TIE1 | PDGFRA 209/4885PDGFRB 191/4885FGFR2 74/4885 |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | PDGFRA 25/4885PDGFRB 44/4885FGFR2 464/4885 |
| US-20210163416-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | PDGFRA 3012/4885PDGFRB 4229/4885FGFR2 1740/4885 |
| US-20180237378-A1 | Asymmetric Bisamidation of Malonic Ester Derivatives | MAL2, ALK, ME1 | PDGFRA 532/4885PDGFRB 486/4885FGFR2 518/4885 |
| US-20170143689-A1 | C-Met Modulator Pharmaceutical Compositions | MET, HGFAC, HGF | PDGFRA 197/4885PDGFRB 53/4885FGFR2 877/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | PDGFRA 1572/4885PDGFRB 2152/4885FGFR2 681/4885 |
| US-11702425-B2 | Bicyclic compounds as kinase modulators, methods and uses thereof | HCCS, PRKAA1, PRKAA2 | PDGFRA 1331/4885PDGFRB 1041/4885FGFR2 1077/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRA 182/4885PDGFRB 90/4885FGFR2 529/4885 |
| US-20170057921-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, HRH2 | PDGFRA 3972/4885PDGFRB 3455/4885FGFR2 4494/4885 |
| US-20180037552-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | PDGFRA 2903/4885PDGFRB 4094/4885FGFR2 1532/4885 |
| US-20250134880-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | MET, HGFAC, HGF | PDGFRA 143/4885PDGFRB 39/4885FGFR2 668/4885 |
| US-20210154185-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRA 3965/4885PDGFRB 3177/4885FGFR2 4410/4885 |
| US-20150133494-A1 | Method of Treating Cancer | MET, ACP3, HGF | PDGFRA 174/4885PDGFRB 100/4885FGFR2 115/4885 |
| US-20200255382-A1 | Method of Treating Cancer and Bone Cancer Pain | TPO, OGFR, CALCR | PDGFRA 2352/4885PDGFRB 2385/4885FGFR2 1963/4885 |
| US-11612597-B2 | Method of treating cancer | MET, HGF, ACP3 | PDGFRA 109/4885PDGFRB 70/4885FGFR2 59/4885 |
| US-20230301980-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885PDGFRB 70/4885FGFR2 59/4885 |
| US-20180311229-A1 | C-Met Modulator Pharmaceutical Compositions | MET, HGFAC, HGF | PDGFRA 143/4885PDGFRB 39/4885FGFR2 668/4885 |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | PDGFRA 25/4885PDGFRB 44/4885FGFR2 464/4885 |
| US-20240307367-A1 | Liquid Dosage Forms to Treat Cancer | FGFR3, KRAS, TP53 | PDGFRA 299/4885PDGFRB 152/4885FGFR2 15/4885 |
| US-12404244-B2 | Pan-KIT kinase inhibitor having quinoline structure and application thereof | KIT, MAP3K7, ABL1 | PDGFRA 747/4885PDGFRB 943/4885FGFR2 1630/4885 |
| US-20240156804-A1 | C-Met Modulator Pharmaceutical Compositions | MET, HGFAC, HGF | PDGFRA 143/4885PDGFRB 39/4885FGFR2 668/4885 |
| US-10166225-B2 | Method for treating osteoporosis | SOST, PTH1R, CALCR | PDGFRA 2429/4885PDGFRB 2933/4885FGFR2 2855/4885 |
| US-12415784-B2 | Cabozantinib compositions and methods of use | KRAS, GSK3B, KSR2 | PDGFRA 176/4885PDGFRB 63/4885FGFR2 43/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | PDGFRA 1935/4885PDGFRB 1297/4885FGFR2 3433/4885 |
| US-20240189298-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRA 3965/4885PDGFRB 3177/4885FGFR2 4410/4885 |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRA 1/4885PDGFRB 2/4885FGFR2 90/4885 |
| US-20200108059-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, HRH2 | PDGFRA 3972/4885PDGFRB 3455/4885FGFR2 4494/4885 |
| US-20220370436-A1 | C-Met Modulator Pharmaceutical Compositions | MET, HGFAC, HGF | PDGFRA 143/4885PDGFRB 39/4885FGFR2 668/4885 |
| US-20160022662-A1 | Cabozantinib Dosage Form and Use in the Treatment of Cancer | ABL1, FER, FLT3 | PDGFRA 59/4885PDGFRB 62/4885FGFR2 118/4885 |
| US-10159666-B2 | Dosing of cabozantinib formulations | MET, ABL1, KRAS | PDGFRA 25/4885PDGFRB 44/4885FGFR2 464/4885 |
| US-11261160-B2 | Process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2S)-hydroxybutanedioate and its polymorphs thereof | SDHA, CYP4B1, PDHA1 | PDGFRA 1163/4885PDGFRB 1722/4885FGFR2 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.